Matches in DBpedia 2014 for { ?s ?p Blinatumomab (MT103) is a drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.The drug was developed by a German-American company Micromet, Inc. in cooperation with Lonza.. }
Showing items 1 to 2 of
2
with 100 items per page.
- Blinatumomab abstract "Blinatumomab (MT103) is a drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.The drug was developed by a German-American company Micromet, Inc. in cooperation with Lonza.".
- Blinatumomab comment "Blinatumomab (MT103) is a drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.The drug was developed by a German-American company Micromet, Inc. in cooperation with Lonza.".